NCT01396499View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Leukemia
Interventions
DRUG

BKM120

Starting dose 80 mg tablets by mouth daily for a 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01396499 - Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias | Biotech Hunter | Biotech Hunter